Evoke Pharma Reports Strong Growth and Patent Expansion

EVOKE PHARMA INC: Company Overview

Evoke Pharma Inc (NASDAQ: EVOK) is a specialty pharmaceutical company headquartered in Solana Beach, California. Founded in 2007, the company focuses on addressing needs in gastrointestinal (GI) disorders, particularly diabetic gastroparesis, which is characterized by delayed gastric emptying and symptoms such as nausea, abdominal pain, bloating, early satiety, and vomiting. Evoke's lead product, GIMOTI® (metoclopramide nasal spray), received FDA approval in 2020 as the first non-oral treatment for diabetic gastroparesis, aiming to address absorption issues associated with traditional oral therapies.

Corporate Structure and Leadership

Evoke operates with a workforce of approximately 2–10 employees. The leadership team includes Chief Executive Officer Matthew J. D’Onofrio, who co-founded the company and has over 30 years of experience in pharmaceutical leadership in areas such as finance, operations, regulatory strategy, and commercialization. Chief Financial Officer Mark Kowieski, CPA, joined in 2022 and became CFO in 2024; he has nearly 25 years of experience in corporate finance and the life sciences industry. Chief Medical Officer Marilyn R. Carlson, D.M.D., M.D., has led the clinical development of GIMOTI since the company’s inception and has regulatory expertise. Chief Commercial Officer Chris Quesenberry oversees the U.S. commercialization strategy in partnership with EVERSANA™, bringing over 30 years of sales and marketing leadership experience in major pharmaceutical firms.

Gastrointestinal Disorders by Towfiqu barbhuiya

Key Developments and News

On March 13, 2025, Evoke Pharma reported fourth-quarter and full-year 2024 financial results. Fourth-quarter revenue increased 24.6% to $3.3 million compared to the prior quarter, while full-year revenue reached $10.2 million, a 97.8% increase over 2023. The company secured $14.3 million in net proceeds from equity financings and warrant exercises, extending its cash runway into the first quarter of 2026. The prescriber base grew to 2,553 physicians, fill rates climbed 72% year-over-year, and patient enrollments increased 22%.

In May 2025, Evoke expanded its intellectual property portfolio with a new patent allowance for GIMOTI covering use in moderate to severe diabetic gastroparesis, which will extend Orange Book exclusivity through December 2036 once issued. At the American College of Gastroenterology meeting in October 2024, GIMOTI data received both the Presidential Poster Award and an Outstanding Research Award for demonstrating an 89% reduction in all-cause emergency department visits and a 66% reduction in office visits among GLP-1 agonist users with diabetic gastroparesis.

On May 15, 2025, Schedule 13G/A filings disclosed that Laurence W. Lytton beneficially owns 61,274 shares (3.9% of the class). The company filed a current report on Form 8-K on July 9, 2025, under Items 8.01 and 9.01, maintaining regulatory transparency.

Financial and Strategic Analysis

Evoke’s share price was $6.87 as of July 9, 2025, representing a 158.27% increase over the measured period, supported by a trading volume of nearly 6.9 million shares on NASDAQ. The revenue trajectory in the first quarter of 2025 showed $3.1 million, up 77% year-over-year, indicating commercial progress for GIMOTI. Collaboration with EVERSANA provides integrated support across sales, marketing, access, and reimbursement, while plans to hire field reimbursement managers aim to assist providers in navigating payer policies.

Evoke intends to in-license or acquire gastroenterology-focused product candidates that utilize novel technologies and intellectual property protection. The patent allowances approved in December 2024 and May 2025 strengthen the company's intellectual property estate, and GIMOTI remains the only FDA-approved non-oral therapy for diabetic gastroparesis since 2020.

Market Position and Industry Context

Diabetic gastroparesis affects millions of patients globally and can hinder oral drug absorption. Prior to GIMOTI's approval, oral metoclopramide (approved in 1979) often provided inconsistent symptom relief. The FDA's Complete Response Letter to a tradipitant application in 2023 and the discontinuation of the compassionate use program for domperidone in the U.S. have positioned GIMOTI as the only FDA-approved non-oral option for this condition.

Evoke's market strategy includes expanding pharmacy partnerships, particularly through the recent transition to the ASPN Pharmacy network, which has improved prescription fulfillment and patient access. The ongoing collection of real-world and clinical data, alongside targeted in-licensing efforts, positions Evoke to strengthen GIMOTI's role in diabetic gastroparesis management.

tl;dr

Evoke Pharma’s fourth-quarter 2024 revenue was $3.3 million, with full-year 2024 sales at $10.2 million, reflecting commercial growth and a 77% increase in first-quarter 2025 revenue. Recent financings of $14.3 million extend operations into Q1 2026. Patent allowances in December 2024 and May 2025 will secure GIMOTI's exclusivity through 2036. Data presented at ACG 2024 demonstrated significant reductions in emergency room and office visits among GLP-1 users. Strategic partnerships with EVERSANA and the ASPN Pharmacy network enhance market access, and plans to expand pharmacy alliances and in-license new gastroenterology therapies support the company’s near-term outlook.